Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Nephrology | Nursing | Pediatrics | Pharmacy | Surgery | Journal

Back to Journal Articles

Steroid-Free Regimen Post-Pediatric Renal Transplant Safe

Last Updated: June 26, 2012.

 

For children, steroid-free immunosuppression safe and effective at three years post-op

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A steroid-free approach to immunosuppression following pediatric renal transplants is safe and effective, according to a study published online June 13 in the American Journal of Transplantation.

TUESDAY, June 26 (HealthDay News) -- A steroid-free approach to immunosuppression following pediatric renal transplants is safe and effective, according to a study published online June 13 in the American Journal of Transplantation.

Minnie M. Sarwala, M.D., Ph.D., of the California Pacific Medical Center in San Francisco, and associates conducted a randomized multicenter study involving 130 children receiving primary kidney transplants between 2004 and 2006. Participants were randomly allocated to steroid-free (SF) or steroid-based (SB) immunosuppression, together with tacrolimus, mycophenolate, and standard or extended-dose daclizumab (SB and SF groups, respectively).

After three years of follow-up the researchers found that the standardized height Z-score change was −0.99 for SF patients, compared with −0.93 in SB patients (P = 0.825). At three years, recipients younger than 5 years showed improved linear growth with SF versus SB treatment (−0.43 versus −1.07; P = 0.019). The rates of biopsy-proven acute rejection at three years post-transplant were similar in both groups (16.7 in SF versus 17.1 in SB; P = 0.94). Patient survival was 100 percent in both groups, with graft survival of 95 and 90 percent in the SF and SB groups, respectively. The SF group showed significantly lower systolic blood pressure and lower cholesterol levels than the SB group.

"In conclusion, complete steroid avoidance, combined with effective induction, tacrolimus and mycophenolate mofetil, provides a new therapeutic standard for safe and effective immunosuppression for renal transplantation of low-risk children with end-stage renal disease," the authors write.

The study was funded by Astellas and Roche Pharmaceuticals.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Imaging Can Detect Response to Dry Mouth Toothpaste Next: Copy Number Variations May Be Linked to Alcohol Dependence

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.